← IONIS PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $346.6m |
$507.7m
+46.46%
|
$599.7m
+18.12%
|
$1.1b
+87.20%
|
$729.3m
-35.04%
|
$810.5m
+11.13%
|
$587.4m
-27.53%
|
$787.6m
+34.10%
|
$705.1m
-10.48%
|
$943.7m
+33.83%
|
$874.1m
-7.38%
|
|
| Cost of Revenue | $0 | $0 | $1.8m |
$4.4m
+140.88%
|
$11.9m
+172.51%
|
$10.8m
-9.25%
|
$14.1m
+30.20%
|
$9.1m
-35.30%
|
$11.2m
+22.80%
|
$15.9m
+41.85%
|
$16.0m
+0.67%
|
|
| Gross Profit (Calculated) | $346.6m |
$507.7m
+46.46%
|
$597.9m
+17.77%
|
$1.1b
+87.04%
|
$717.3m
-35.85%
|
$799.6m
+11.47%
|
$573.3m
-28.31%
|
$778.5m
+35.81%
|
$693.9m
-10.87%
|
$927.8m
+33.70%
|
— | |
| Research and Development Expense | $340.4m | $372.5m | $411.9m | $461.5m | $531.0m | $638.2m | — | — | — | $915.6m | $924.7m | |
| General and Administrative Expense | $48.6m | $108.5m | $244.6m | $286.6m | $354.3m | $186.3m | $150.3m | $232.6m | $267.5m | $393.9m | $527.8m | |
| Amortization of Intangible Assets | — | — | $1.8m | $1.9m | $2.1m | $2.4m | $2.4m | $2.6m | $2.3m | $2.4m | — | |
| Operating Lease, Expense | — | — | — | $3.6m | $3.7m | $3.4m | $8.3m | $23.1m | $23.2m | $26.0m | — | |
| Operating Expenses | $392.9m | $483.1m | $661.0m | — | — | — | — | — | — | — | $1.5b | |
| Operating Income (Loss) | ($46.3m) |
$24.5m
+152.97%
|
($61.4m)
-350.15%
|
$365.9m
+696.17%
|
($172.1m)
-147.03%
|
($30.2m)
+82.46%
|
($410.2m)
-1258.88%
|
($353.7m)
+13.76%
|
($475.1m)
-34.31%
|
($381.7m)
+19.66%
|
($594.4m)
-55.73%
|
|
| Interest Expense | $38.8m | $44.8m | $44.8m | $48.8m | $45.0m | $9.3m | $8.1m | $12.7m | $17.0m | $17.3m | $82.4m | |
| Investment Income, Net | $5.4m | $7.8m | $30.2m | $52.2m | $30.6m | $10.0m | $25.3m | $89.0m | $107.0m | $97.8m | — | |
| Gain (Loss) on Investments | $56k | — | ($210k) | $192k | $16.5m | $10.1m | ($7.3m) | ($1.9m) | ($2.9m) | $10.2m | — | |
| Other Nonoperating Income (Expense) | — | — | ($182k) | ($686k) | ($62k) | ($1.1m) | ($7.3m) | $14.3m | $1.3m | ($15.4m) | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | ($11.8m) | ($69.6m) | $344.3m | ($172.7m) | ($30.0m) | ($258.5m) | ($334.7m) | ($460.7m) | ($381.2m) | ($562.0m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($83.6m) | — | — | — | — | ($29.1m) | ($258.0m) | ($334.0m) | ($460.1m) | ($379.6m) | ($562.0m) | |
| Current Income Tax Expense (Benefit) | $2.9m | ($6.0m) | ($630k) | $50.6m | $3.5m | ($551k) | $11.7m | $32.3m | ($6.2m) | $1.8m | $3.2m | |
| Income Tax Expense (Benefit) | $2.9m | ($6.0m) | ($291.1m) | $43.5m | $316.7m | ($551k) | $11.7m | $32.3m | ($6.2m) | $1.8m | $3.2m | |
| Net Income (Loss) Attributable to Parent | ($86.6m) |
($6.0m)
+93.10%
|
$273.7m
+4685.28%
|
$294.1m
+7.45%
|
($451.3m)
-253.42%
|
($28.6m)
+93.66%
|
($269.7m)
-843.18%
|
($366.3m)
-35.80%
|
($453.9m)
-23.92%
|
($381.4m)
+15.97%
|
($565.2m)
-48.19%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | — | $9.7m |
$276.9m
+2765.83%
|
$296.6m
+7.11%
|
($451.5m)
-252.24%
|
— | — | — | — | — | ($565.2m) | |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | ($11.3m) | ($58.8m) | $9.1m | ($35.5m) | $0 | $0 | — | — | — | ($565.2m) | |
| Earnings Per Share, Basic | — | $0.08 | $2.09 | $2.12 | ($3.23) | ($0.20) | ($1.90) | ($2.56) | ($3.04) | ($2.38) | ($3.48) | |
| Earnings Per Share, Diluted | — | $0.08 | $2.07 | $2.08 | ($3.23) | ($0.20) | ($1.90) | ($2.56) | ($3.04) | ($2.38) | ($3.48) | |
| Weighted Average Number of Shares Outstanding, Basic | — | 124.0m | 132.3m | 140.0m | 139.6m | 141.0m | 141.8m | 143.2m | 149.5m | 160.0m | 163.1m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | 126.1m | 134.1m | 142.9m | 139.6m | 141.0m | 141.8m | 143.2m | 149.5m | 160.0m | 163.1m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | — | — | — | $756.7m | $901.3m | $840.6m | $997.6m | $1.1b | $1.2b | $1.3b | — | |
| Realized Investment Gains (Losses) | — | — | — | — | — | $1.1m | ($224k) | ($1.6m) | ($2.9m) | $9.3m | — | |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | — | — | — | — | — | — | — | — | $131.0m | $135.7m | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.